Wanjia CSI Hong Kong Connect Innovative Drug Exchange Traded Fund Units

Wanjia CSI Hong Kong Connect Innovative Drug Exchange Traded Fund Units is offered by Wanjia, a leading player in the field of passive investments.

The ETF is listed in CNY.

European investors may incur additional costs for currency exchange and transaction fees.

No, Wanjia CSI Hong Kong Connect Innovative Drug Exchange Traded Fund Units does not comply with the EU UCITS investor protection directives.

The P/E ratio of Wanjia CSI Hong Kong Connect Innovative Drug Exchange Traded Fund Units is 24.61.

Wanjia CSI Hong Kong Connect Innovative Drug Exchange Traded Fund Units tracks the performance of the CSI Hong Kong Stock Connect Innovative Drug Index - CNY - Benchmark TR Net.

Wanjia CSI Hong Kong Connect Innovative Drug Exchange Traded Fund Units is domiciled in CN.

The fund was launched on 9/13/2024.

The Wanjia CSI Hong Kong Connect Innovative Drug Exchange Traded Fund Units mainly invests in Healthcare companies.

The NAV of Wanjia CSI Hong Kong Connect Innovative Drug Exchange Traded Fund Units amounts to 1.63 M CNY.

The price-to-book ratio is 3.451.

Investments can be made through brokers or financial institutions that provide access to trading ETFs.

The ETF is traded on the stock exchange, similar to stocks.

Yes, the ETF can be held in a regular securities account.

The ETF is suitable for both short-term and long-term investment strategies, depending on the investor's goals.

The ETF is valued on a daily stock exchange basis.

Information on dividends should be requested from the provider's website or your broker.

The risks include market fluctuations, currency risks, and the risk associated with smaller companies.

The ETF is obligated to report regularly and transparently on its investments.

The performance can be viewed on Eulerpool or directly on the provider's website.

Further information can be found on the official website of the provider.